Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Company Info
Leadership
Income Statement
Revenue & Margin Trend
| Period | Revenue | OpEx | EBITDA | Net Income | EPS |
|---|---|---|---|---|---|
| 2022 | $28.54B | $13.63B | $8.66B | $6.24B | $6.57 |
| 2023 | $34.12B▲ | $16.72B | $11.85B | $5.24B▼ | $5.80 |
| 2024 | $45.04B▲ | $19.59B | $18.81B | $10.59B▲ | $11.71 |
| 2025 | $65.18B▲ | $24.43B | $31.69B | $20.64B▲ | $22.95 |
Balance Sheet
Assets Distribution
Liabilities & Equity
Cash Flow
Cash Flow Mix
FCF Generation
The company converts 35% of operating cash flow into free cash flow, providing ample flexibility for capital allocation.
CapEx Burden
Capital expenditures consume $11B of operating cash. Monitor for maintenance vs. growth CapEx split.
Financial Ratios
Profitability
Liquidity & Leverage
Returns
Historical Trends
Revenue
+31.7% CAGRNet Income
+49.0% CAGREPS
+51.7% CAGRDividends & Yield
Dividend Safety Assessment
The payout ratio of 23% suggests ample room for dividend growth and sustainability. The company retains over half of its earnings for reinvestment.
Recent Dividend Payments
| Date | Amount |
|---|---|
| 2026-08-14 | $1.73 |
| 2026-05-15 | $1.73 |
| 2026-02-13 | $1.73 |
| 2025-11-14 | $1.50 |
| 2025-08-15 | $1.50 |
| 2025-05-16 | $1.50 |
| 2025-02-14 | $1.50 |
| 2024-11-15 | $1.30 |
| 2024-08-15 | $1.30 |
| 2024-05-15 | $1.30 |
Institutional Ownership
Moderate Institutional Support
Top 3 institutional holders control 22.5% of shares, providing a stable foundation of institutional capital.
Retail Influence
Lower institutional concentration means retail sentiment and broader market trends may drive price action more noticeably.
Top Institutional Holders
Top ETFs Holding
Market Events
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1997-10-16 | Forward | 2:1 |
| 1995-12-21 | Forward | 2:1 |
| 1989-05-01 | Forward | 2:1 |
| 1986-01-30 | Forward | 2:1 |
Market Intelligence
Analyst Consensus
Earnings History
| Period | Est. EPS | Act. EPS | Surprise |
|---|---|---|---|
| 2025-09 | $5.89 | $7.02 | +19.1% |
| 2025-12 | $6.91 | $7.54 | +9.1% |
| 2026-03 | $6.79 | $8.55 | +25.9% |
| 2026-06 | $6.58 | $8.38 | +27.3% |